Asset sale Completed

Axsome Therapeutics acquisition of Exclusive global rights to TAK-063 (balipodect)

Advisers

Exclusive global rights to TAK-063 (balipodect)

Target

Not disclosed

Target
Exclusive global rights to TAK-063 (balipodect)
Acquirer
Axsome Therapeutics
Seller
Takeda Pharmaceutical Co.
Buyer based in
United States
Seller based in
Japan
Completed
3 Apr 2026
Sector
Pharma
Tags
Pharma, Drug Development

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.